Compare PANL & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PANL | DCTH |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | 156 |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.2M | 372.5M |
| IPO Year | 2015 | 2015 |
| Metric | PANL | DCTH |
|---|---|---|
| Price | $7.23 | $10.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 720.7K | 477.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $385,088,209.00 | N/A |
| Revenue This Year | $0.72 | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | $34.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.46 | $8.12 |
| 52 Week High | $9.39 | $16.68 |
| Indicator | PANL | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 46.90 |
| Support Level | $7.10 | $10.55 |
| Resistance Level | $7.35 | $11.14 |
| Average True Range (ATR) | 0.38 | 0.49 |
| MACD | -0.12 | -0.09 |
| Stochastic Oscillator | 1.65 | 28.19 |
Pangaea Logistics Solutions Ltd and its subsidiaries collectively, Pangaea or the Company, provide seaborne drybulk logistics and transportation services as well as terminal and stevedoring services. Pangaea utilizes its logistics expertise to service a broad base of industrial customers who require the transportation of a wide variety of dry bulk cargoes, including grains, coal, iron ore, pig iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The Company's operating segments include the shipping segment: The Company's operating segments include the shipping segment and six terminal and stevedoring operating segments. The company operates in the USA, Germany, Canada, Singapore, the United Kingdom, and other countries, with maximum from the USA and others.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.